Clinical Trials Directory

Trials / Completed

CompletedNCT02271607

The Effect and Safety of Moxibustion Therapy for Overactive Bladder Patients

A Pilot Study About The Effects of Indirect-Moxibustion on Bladder- Functional Improvement and Symptoms Management in Patients With Overactive Bladder: A Randomized Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Korean Medicine Hospital of Pusan National University · Academic / Other
Sex
All
Age
20 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This pragmatic randomized controlled study aimed to evaluate the effectiveness and safety of moxibustion therapy on overactive bladder (OAB) patients.

Detailed description

Patients who diagnosed as overactive bladder aged 20 to 75 years old will be divided into two groups, one is moxibustion-therapy and the other is waiting-list group. Patients who belong to moxibustion therapy group will be treated moxibustion for 12 times by a Korean Medicine doctor. Patients who belong to waiting-list group will be prohibited to get any treatment including moxibustion for relieve the symptoms of overactive bladder, and the same moxibustion therapy with moxbiustion-therapy group will be conducted after 4 weeks. Overactive bladder symptom score (OABSS), overactive bladder-validated 8-question (OAB-V8) will be measured to evaluate the effectiveness. The number of side effect will be measured to evaluate the safety. The skin temperature of CV4, SP6 and LR3, and the tympanic temperature will be measured to study treatment mechanism.

Conditions

Interventions

TypeNameDescription
DEVICEmoxibustionThe treatment schedule is three times per week for four weeks. Indirect moxa pillars and indirect-container moxibustion will be used.

Timeline

Start date
2014-10-01
Primary completion
2015-12-01
Completion
2015-12-01
First posted
2014-10-22
Last updated
2016-03-14

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02271607. Inclusion in this directory is not an endorsement.